Bank Of America Corp Anixa Biosciences Inc Transaction History

Bank Of America Corp

$1.17 Trillion
Q4 2024

A detailed history of Bank Of America Corp transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Bank Of America Corp holds 210,257 shares of ANIX stock, worth $643,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares

210,257

Previous 217,148 3.17%

Holding current value

$643,386

Previous $684,000 23.83%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.48 - $3.97 $17,089 - $27,357	-6,891 Reduced 3.17%	210,257 $521,000
Q3 2024 Nov 14, 2024	BUY	$2.21 - $3.48 $517 - $814	234 Added 0.11%	217,148 $684,000
Q2 2024 Aug 14, 2024	BUY	$2.21 - $3.35 $221,000 - $335,000	100,000 Added 85.53%	216,914 $479,000
Q1 2024 May 15, 2024	BUY	$3.08 - $5.02 $308,000 - $501,999	100,000 Added 591.23%	116,914 $364,000
Q4 2023 Feb 14, 2024	SELL	$2.85 - $4.19 $1,980 - $2,912	-695 Reduced 3.95%	16,914 $65,000
Q2 2023 Aug 14, 2023	BUY	$3.0 - $5.97 $216 - $429	72 Added 0.41%	17,609 $56,000
Q4 2022 Feb 10, 2023	BUY	$3.78 - $5.81 $15,588 - $23,960	4,124 Added 30.75%	17,537 $74,000
Q3 2022 Nov 14, 2022	BUY	$2.81 - $6.15 $26,593 - $58,203	9,464 Added 239.66%	13,413 $66,000
Q2 2022 Aug 12, 2022	BUY	$2.55 - $4.1 $1,081 - $1,738	424 Added 12.03%	3,949 $12,000
Q1 2022 May 16, 2022	SELL	$2.5 - $3.42 $3,850 - $5,266	-1,540 Reduced 30.4%	3,525 $10,000
Q4 2021 Feb 08, 2022	SELL	$2.88 - $5.5 $843 - $1,611	-293 Reduced 5.47%	5,065 $15,000
Q3 2021 Nov 15, 2021	BUY	$3.57 - $5.6 $19,053 - $29,887	5,337 Added 25414.29%	5,358 $26,000
Q2 2021 Sep 13, 2021	BUY	$3.46 - $4.92 $72 - $103	21 New	21 $0

Others Institutions Holding ANIX

# of Institutions

Shares Held

5.73M

Call Options Held

7.1K

Put Options Held

26.7K

View Full List

About Anixa Biosciences Inc

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $93.8M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

More about ANIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Anixa Biosciences Inc Transaction History